- Home
- ARTW vs BIVI Comparison
ARTW vs BIVI Comparison
Compare ARTW & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARTW | BIVI |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.5M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ARTW | BIVI |
|---|---|---|
| Price | $2.70 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 88.9K |
| Earning Date | 04-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $0.88 |
| 52 Week High | $4.69 | $9.09 |
Technical Indicators
Market Signals| Indicator | ARTW | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 52.79 |
| Support Level | $2.07 | $1.42 |
| Resistance Level | $2.96 | $1.52 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 48.21 | 73.54 |
Price Performance
Historical ComparisonAbout ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.